Inhibition by hydroxy-N-methyl elliptinium of precancerous mammary hyperplastic alveolar nodule formation in mice.
Daily subcutaneous injections of 5 micrograms hydroxy-N-methyl elliptinium for 4 weeks in a high mammary tumor strain of SHN virgin mice was found to decrease the number of precancerous mammary hyperplastic alveolar nodules (HAN) associated with the increase in the number of ghosts, the remnants of regressed HAN. On the other hand, the treatment had little influence on the normal mammary lobulo-alveolar system, serum prolactin level, estrous cycle and endocrine organ weights. The results have demonstrated that elliptinium can inhibit the formation of HAN and induce their regression with no modulation of endogenous conditions of mammotropic hormones.
D000470:Alkaloids / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D004611:Ellipticines / Q000627:therapeutic use*; D004702:Endocrine Glands / Q000187:drug effects; D004971:Estrus / Q000187:drug effects; D005260:Female; D006965:Hyperplasia / Q000517:prevention & control; D008325:Mammary Neoplasms, Experimental / Q000503:physiopathology / Q000517:prevention & control*; D051379:Mice; D008815:Mice, Inbred Strains; D009929:Organ Size / Q000187:drug effects; D011230:Precancerous Conditions / Q000503:physiopathology / Q000517:prevention & control*; D011247:Pregnancy; D011388:Prolactin / Q000097:blood
D000470:Alkaloids; D000970:Antineoplastic Agents; D004611:Ellipticines; C027767:elliptinium; D011388:Prolactin